Table 1.
Clinical trials of ESC/iPSC-based studies in ocular therapy.
| Cell type | Disease | Institute/location | Phase | Status of trial | References/sources |
|---|---|---|---|---|---|
| ESC-derived RPE | Dry AMD | Astellas Institute for Regenerative Medicine, USA | Phase I Phase II |
Completed | NCT01344993 |
| ESC-derived RPE | Stargardt's macular dystrophy | Astellas Institute for Regenerative Medicine, USA | Phase I Phase II |
Completed | NCT01345006 |
| ESC-derived RPE | Stargardt's macular dystrophy | Astellas Institute for Regenerative Medicine, UK | Phase I Phase II |
Completed | NCT01469832 |
| iPSC-derived RPE | Wet AMD | Rikagaku Kenkyûsho (RIKEN) Institute, Japan | Phase I | Halted | [42] |
| hESC-derived RPE | Wet AMD | Pfizer and University College, London, UK | Phase I | Ongoing | NCT01691261 |
| hESC-derived RPE | Myopic macular degeneration | University of California and Ocata Therapeutics, USA | Phase I Phase II |
Withdrawn | NCT02122159 |
| hESC-derived RPE | Dry AMD | Cell Cure Neurosciences Ltd., Israel | Phase I Phase II |
Recruiting | NCT02286089 |
AMD, age-related macular degeneration; hESC, human embryonic stem cell; iPSC, induced pluripotent stem cell; MMD, myopic macular degeneration; RPE, retinal pigment epithelium.